Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises in connection with the sale of Fiskarhedenvillan
Mandate

Vinge advises in connection with the sale of Fiskarhedenvillan

March 17, 2020 M&A

Vinge has advised Litorina and other shareholders in connection with the sale of Fiskarhedenvillan to the company’s CEO and a group of industrial partners.

Fiskarhedenvillan sells residential properties primarily to private individuals in Sweden, Denmark and Finland and has a turnover of approximately SEK 700 million on an annual basis.

Vinge’s team primarily consisted of Johan Winnerblad, Joacim Rydergård, Anna Thoms, Olivia Belding, Rikard Lindahl, William Kåge, Louise Brorsson Salomon and Viktoria Owetz Leyva.

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

 SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026